Evidence map›Paper›PMID 35917312›Full record

ArticlePloS one2022

Biodegradable microneedle patch for delivery of meloxicam for managing pain in cattle.

David A Castilla-Casadiego, Katherine A Miranda-Muñoz, Jesse L Roberts, Anne D Crowell, David Gonzalez-Nino, Dipankar Choudhury, Frank O Aparicio-Solis, Shannon L Servoss, Adrianne M Rosales, Gary Prinz and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

David A Castilla-CasadiegoRalph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas, United States of America.
Katherine A Miranda-MuñozDepartment of Biomedical Engineering, College of Engineering, University of Arkansas, Fayetteville, Arkansas, United States of America.
Jesse L RobertsRalph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas, United States of America.
Anne D CrowellMcketta Department of Chemical Engineering, University of Texas at Austin, Austin, Texas, United States of America.ORCID 0000-0002-7035-1100
David Gonzalez-NinoDepartment of Civil Engineering, University of Arkansas, 4190 Bell Engineering Center, Fayetteville, Arkansas, United States of America.ORCID 0000-0001-5787-6888
Dipankar ChoudhuryDepartment of Mechanical Engineering, University of Arkansas, 204 Mechanical Engineering Building, Fayetteville, Arkansas, United States of America.
Frank O Aparicio-SolisRalph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas, United States of America.
Shannon L ServossRalph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas, United States of America.ORCID 0000-0003-3075-5423
Adrianne M RosalesMcketta Department of Chemical Engineering, University of Texas at Austin, Austin, Texas, United States of America.
Gary PrinzDepartment of Civil Engineering, University of Arkansas, 4190 Bell Engineering Center, Fayetteville, Arkansas, United States of America.ORCID 0000-0003-2579-3214
Min ZouDepartment of Mechanical Engineering, University of Arkansas, 204 Mechanical Engineering Building, Fayetteville, Arkansas, United States of America.
Yuntao ZhangDepartment of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, 228 Coles Hall, Manhattan, Kansas, United States of America.
Johann F CoetzeeDepartment of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, 228 Coles Hall, Manhattan, Kansas, United States of America.
Lauren F GreenleeRalph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas, United States of America.
Jeremy PowellDepartment of Animal Sciences, University of Arkansas, B110 Agriculture, Food and Life Sciences Building, Fayetteville, Arkansas, United States of America.
Jorge AlmodovarRalph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas, United States of America.ORCID 0000-0002-1151-3878
University of Arkansas at Fayetteville · USKansas State University · USThe University of Texas at Austin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microneedle patches are a promising source for transdermal diffusion of macromolecules and are designed to painlessly penetrate the skin. In this study, a biodegradable chitosan microneedle patch to deliver meloxicam for managing pain in cattle was tested. The potential of reuse of the polymeric solution to fabricate the patches, optimization of fabrication, morphological analysis of the microneedle patch and analysis of preservation of the chemical composition after sterilization were evaluated. In-vitro analysis consisted of studying in-vitro penetration mechanical properties, compression testing analysis of microneedle patch, and in-vitro drug release analysis. In-vivo studies were performed to analyze the dissolution capability of the microneedle patch. Results regarding the physical characteristics, chemical composition, and mechanical properties confirmed that rheological properties of the chitosan solution, present significant differences over time, demonstrating that reusing the solution on the fourth day results in failure patches. Morphological characteristics and chemical composition studies revealed that the process of sterilization (ethylene oxide gas) needed for implanting the patches into the skin did not affect the properties of microneedle patches. In-vitro studies showed that approximately 33.02 ± 3.88% of the meloxicam was released over 7 days. A full penetration of the microneedles into the skin can be obtained by applying approximately 3.2 N. In-vivo studies demonstrated that microneedle patches were capable of swelling and dissolving, exhibiting a dissolution percentage of more than 50% of the original height of microneedle after 7 days. No abnormal tissue, swelling, or inflammation was observed in the implanted area. The results of this work show that chitosan biodegradable microneedle patches may be useful to deliver meloxicam to improve pain management of cattle with positive effects for commercial manufacturing.

Indexed as

ChitosanAdministration, CutaneousAnimalsCattleDrug Delivery SystemsMeloxicamNeedlesPainPain ManagementSkinTransdermal PatchChitosanMeloxicam

Identifiers

PMID35917312
PMCPMC9345335
OpenAlexW4289520301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.